Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
GetUG-AFU 17 was a randomized, open-label, multicentre, phase 3 trial done at 46 French hospitals. 5-year event-free survival was 92% in the adjuvant radiotherapy group. Acute grade 3 or worse toxic effects occurred in six (3%) of 212 patients.
